Press release


ABIONYX Pharma announces approval
of all resolutions put to the vote at its
Combined General Meeting

Toulouse, FRANCE, Lakeland MI, USA, June 27th, 2025, 6:30 p.m. CEST - ABIONYX Pharma,
(FR0012616852 - ABNX - PEA PME eligible), a new generation biotech company dedicated to the
discovery and development of innovative therapies based on the world’s only natural recombinant
apoA-I, announces that all resolutions presented at its Combined General Meeting were approved.

ABIONYX Pharma would like to thank all shareholders present, represented or having voted by post
for their commitment and support at this General Meeting.

The minutes of the General Meeting and the results of the votes by resolution are available on the
Company's website in the Shareholder Meeting section.


About ABIONYX Pharma
ABIONYX Pharma is a next-generation biotech company focused on developing innovative medicines for diseases where
there is no effective or existing treatment, even the rarest ones. The company expedites the development of novel
therapeutics through an extensive expertise in lipid science and a differentiated apoA-I-based technology platform. ABIONYX
Pharma is committed to radically improving treatment outcomes in Sepsis and critical care.

Contacts

NewCap NewCap
Investor relations Media relations
Louis-Victor Delouvrier Arthur Rouillé
Théo Martin abionyx@newcap.eu
abionyx@newcap.eu +33 (0)1 44 71 94 98
+33 (0)1 44 71 98 53




1/1